London, June 10, 2026, 12:04 BST
GSK plc shares steadied near midday Wednesday, trading at 1,905.5p, up 0.11%, after investors spent a day weighing the cost of its $10.6 billion cash deal for Nuvalent against the chance to add two late-stage lung-cancer medicines that could reach the U.S. market this year. The stock had fallen 0.5% on Tuesday after the acquisition was announced.
The deal is the reason GSK is in focus. The London-listed drugmaker agreed to pay $124 a share in cash for Nuvalent, a Boston clinical-stage biotech, valuing the company at $10.6 billion, or $9.4 billion after cash acquired. The price is 40% above Nuvalent’s last close and 26% above its 30-day volume-weighted average price, a trading measure that reflects the average price investors paid over a period, adjusted for volume.
The first read from the market was cautious. GSK’s shares fell as low as 1,839p on Tuesday before closing at 1,903.5p, according to Investing.com data, while Nuvalent’s New York-listed stock surged almost to the offer price as shareholders priced in the takeover premium. That split reaction is typical in large pharma deals: target investors get the immediate cash uplift, while the buyer absorbs regulatory, financing and execution risk.
GSK is buying two drugs now under U.S. Food and Drug Administration review: zidesamtinib for ROS1-positive non-small cell lung cancer and neladalkib for ALK-positive non-small cell lung cancer. Non-small cell lung cancer, or NSCLC, is the most common form of lung cancer; ROS1 and ALK refer to genetic changes that can drive tumour growth. GSK said the FDA target decision dates are Sept. 18 for zidesamtinib and Nov. 27 for neladalkib.
Chief Executive Luke Miels called the two lead drugs “potential best-in-class assets” and said they could launch this year if approved by the FDA. GSK also said the purchase adds a third lung-cancer asset, NVL-330, now in phase I trials for HER2-altered NSCLC. GSK
The financial trade-off is what investors are testing. GSK left its 2026 guidance unchanged, still forecasting 7% to 9% growth in core operating profit and core earnings per share. Core EPS means earnings per share adjusted for items the company excludes from its preferred performance measure. The company expects low single-digit percentage dilution to core EPS in 2026, 2027 and 2028, then accretion, or a positive contribution, to core EPS in 2029 after synergies and spending reprioritisation.
GSK also tried to answer balance-sheet questions quickly. It said the transaction would be funded mainly with new and existing debt facilities plus cash, with no expected impact on its credit rating, and reaffirmed its expected 70p dividend for 2026. That matters because large cash biotech acquisitions can unsettle income investors when they threaten leverage, buybacks or dividends.
The strategic logic is clear enough: GSK wants a faster oncology buildout and sees Nuvalent as a way into targeted lung cancer, not just another early research bet. The company said the acquisition should contribute to revenue growth from 2027 and add to its existing ambition for more than £40 billion in sales by 2031, while helping profit through the 2028-2030 loss-of-exclusivity period for dolutegravir. Loss of exclusivity is the point when patent or regulatory protection fades and cheaper competition can enter.
There is also a competitive angle. Investor’s Business Daily reported that Wedbush analyst David Nierengarten saw a low chance of a competing bid, noting that larger oncology players such as Pfizer, Roche and Bristol Myers Squibb already have similar capabilities, while GSK lacked a targeted lung-cancer portfolio. That makes Nuvalent a cleaner strategic fit for GSK than for some rivals, but not a cheap one.
The risk is not theoretical. The tender offer has not yet started, and the transaction still needs a majority of Nuvalent Class A shares to be tendered and U.S. Hart-Scott-Rodino antitrust clearance. The SEC filing also warns that expected benefits may not arrive on schedule, regulatory approvals may not be obtained as planned, and future clinical or commercial results for zidesamtinib and neladalkib may differ from current expectations.
For now, the stock’s small rebound suggests investors are not rejecting the deal outright; they are waiting for proof that GSK can turn a heavy upfront cheque into approved drugs, launches and earnings growth. The next scheduled investor marker is July 28, when GSK says it will report second-quarter results and give an update on portfolio growth opportunities, before the two FDA decision dates become the larger test in September and November.
